

# Hyperglycaemic memory affects the neurovascular unit of the retina in a diabetic mouse model

Patrick Friedrichs<sup>1</sup> · Andrea Schlotterer<sup>1</sup> · Carsten Sticht<sup>2</sup> · Matthias Kolibabka<sup>1</sup> · Paulus Wohlfart<sup>3</sup> · Axel Dietrich<sup>3</sup> · Thomas Linn<sup>4</sup> · Grietje Molema<sup>5</sup> · Hans-Peter Hammes<sup>1</sup>

Received: 15 November 2016 / Accepted: 14 February 2017 / Published online: 20 March 2017  
© Springer-Verlag Berlin Heidelberg 2017

## Abstract

**Aims/hypothesis** The aim of this study was to evaluate damage to the neurovascular unit in a mouse model of hyperglycaemic memory.

**Methods** A streptozotocin-induced mouse model of diabetes (C57BL/6J background) received insulin-releasing pellets and pancreatic islet-cell transplantation. Damage to the neurovascular unit was studied by quantitative retinal morphometry for microvascular changes and microarray analysis, with subsequent functional annotation clustering, for changes of the retinal genome. **Results** Sustained microvascular damage was confirmed by persistent loss of pericytes in the retinal vasculature (PC/mm<sup>2</sup>): compared with healthy controls (1981 ± 404 PC/mm<sup>2</sup>), the pericyte coverage of the retinal vasculature was significantly reduced in diabetic mice (1571 ± 383 PC/mm<sup>2</sup>,  $p < 0.001$ ) and transplanted mice (1606 ± 268 PC/mm<sup>2</sup>,  $p < 0.001$ ). Genes meeting the criteria for hyperglycaemic memory were attributed to the cytoskeletal and nuclear cell compartments of the neurovascular unit. The most prominent regulated genes in the

cytoskeletal compartment were *Ddx51*, *Fgd4*, *Pdlim7*, *Utp23*, *Cep57*, *Csrp3*, *Eml5*, *Fhl3*, *Map1a*, *Mapk1ip1*, *Mnda*, *Neil2*, *Parp2*, *Myl12b*, *Dynll1*, *Stag3* and *Sntg2*, and in the nuclear compartment were *Ddx51*, *Utp23*, *Mnda*, *Kmt2e*, *Nr6a1*, *Parp2*, *Cdk8*, *Srsf1* and *Zfp326*.

**Conclusions/interpretation** We demonstrated that changes in gene expression and microvascular damage persist after euglycaemic re-entry, indicating memory.

**Data availability** The datasets generated during and/or analysed during the current study are available in the GEO repository, GSE87433, [www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=idmbysgctluxviv&acc=GSE87433](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=idmbysgctluxviv&acc=GSE87433).

**Keywords** Animal · Microarray · Microvascular disease · Mouse · Retinopathy

## Abbreviations

6 W/12 W	6 weeks/12 weeks
DCCT	Diabetes Control and Complications Trial
DC	Diabetic control group
NC	Normal control group
STZ	Streptozotocin
Tx	Transplanted

## Introduction

Hyperglycaemic memory is part of the pathogenesis of diabetic retinopathy [1, 2]. Perpetuation of oxidative stress, irreversible accumulation of AGEs and hyperglycaemia-induced epigenetic changes are possible underlying mechanisms.

In diabetic dogs, retinopathy develops during euglycaemia after initial hyperglycaemia. In the human retina, the effect of a less-well-controlled period is perpetuated into the period of

✉ Andrea Schlotterer  
Andrea.Schlotterer@medma.uni-heidelberg.de

<sup>1</sup> Fifth Medical Department, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany

<sup>2</sup> Center of Medical Research, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany

<sup>3</sup> Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany

<sup>4</sup> Clinical Research Unit, Centre of Internal Medicine, Justus-Liebig-University Giessen, Giessen, Germany

<sup>5</sup> Department of Pathology and Medical Biology, Medical Biology section, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

euglycaemic control. In the Diabetes Control and Complications Trial (DCCT), progression to diabetic retinopathy was increased in the conventional treatment group. In the follow-up study, this effect persisted even after equalising HbA<sub>1c</sub> levels.

Cell culture experiments revealed several important mechanisms of hyperglycaemic memory. The transcription factor mSin3A is persistently activated upon short cellular exposure to high glucose, regulating angiopoietin-2, an angiogenic growth factor and regulator of diabetic pericyte dropout [3]. Short exposure to high glucose also induces epigenetic modifications and subsequent downregulation of antioxidant defence proteins (e.g. mediated by the sustained recruitment of SET7 methyltransferase to the NFκB p65 promoter [4]).

Hyperglycaemic memory has mainly been studied in short-term (cell culture) or long-term animal models, such as the studies by Kowluru [5]. Therefore, the aim of this study was to evaluate a novel model of intermediate-term hyperglycaemic memory using islet transplantation to enable the study of subsequent early structural alterations in the neurovascular unit of the retina in diabetic retinopathy.

## Methods

**Animals** Male C57BL/6J mice (Charles River, Frankfurt, Germany) were housed under a 12 h light–dark cycle with free access to food and water. Experiments were conducted in accordance with the Association for Research in Vision and Ophthalmology statement for the Use of Animals in Ophthalmic and Vision Research. The study was approved by the Regional Commission in Karlsruhe, Germany.

**Experimental groups** Eight-week-old streptozotocin (STZ)-induced diabetic mice (diabetic control [DC]), 8-week-old STZ-induced diabetic mice receiving isogenic pancreatic islet transplantation (Tx) after 6 weeks of diabetes (DC+Tx) and age-matched controls (non-diabetic control [NC]) were analysed after 6 weeks (6W) and 12 weeks (12W). Use of isogenic animals and sterile conditions ensured the absence of immune responses and surgical complications. All mice were euthanised under general anaesthesia.

**Diabetes induction** Diabetes was induced by intraperitoneal injection of STZ (160 mg/kg body weight; Sigma-Aldrich, Munich, Germany) in 8-week-old mice. Stable hyperglycaemia was confirmed 7 days after injection by blood glucose >16.7 mmol/l. Body weight and blood glucose were measured throughout the experiment (BGStar; Sanofi-Aventis, Frankfurt am Main, Germany; limited to 33.3 mmol/l). HbA<sub>1c</sub> was measured using affinity chromatography (In2it; Biorad, Munich, Germany).

**Islet transplantation** Transplantation of pancreatic islet cells was performed by the Clinical Research Unit, Giessen (TL). Islets were taken from 8-week-old male C57BL/6J mice (Janvier Labs, Saint-Berthevin, France). Pancreatic islet-cell isolation was performed using pancreatic collagenase digestion and handpicked selection [6]. About 300 islets were injected below the kidney capsule of the recipient mice after 6 weeks of diabetes induction. To support a basal insulin release of the islet graft, insulin-releasing pellets (LinBit; LinShin Canada, Toronto, ON, Canada), each releasing insulin at 0.1 U/24 h, were placed subcutaneously below the mid dorsal skin. The number of pellets placed in each recipient mouse, estimated by the targeted reduction of blood glucose levels (< 13.9 mmol/l), was two to four.

**Retinal digestion** Retinas were isolated after overnight fixation of frozen eyes (−80°C) in 4% buffered formalin and were digested using a trypsin-based digestion method. Four to six retinas from each group were analysed morphometrically. In each retina, ten fields were randomly selected using ×400 magnification and CellF analysing software (Olympus, Hamburg, Germany). The cell numbers were normalised to relative capillary density (cell number/mm<sup>2</sup> capillary area).

**RNA isolation** Frozen eyes were dissected and the retinas were extracted and immediately suspended in Trizol reagent (Invitrogen, Carlsbad, CA, USA). Zirconium oxide beads (1 mm, RNase-free; Next Advance, Averill Park, NY, USA) and a Bullet Blender (Next Advance) were used for retinal homogenisation. RNA was extracted using Trizol. RNA quality was verified using a Bioanalyzer 2100 (Agilent, Santa Clara, CA, USA) and quantity measured by spectroscopy using an Infinite200 PRO NanoQuant System (Tecan, Männedorf, Switzerland).

**Gene expression profiling** Gene expression profiling ( $n = 5$  or 6 per group) was performed using Affymetrix GeneChip Mouse Gene 2.0 ST Array. Biotinylated antisense cRNA was then prepared in accordance with a standard labelling protocol. All protocols and equipment were from Affymetrix (High Wycombe, UK).

**Bioinformatics** A custom CDF Version 19 with Entrez-based gene definitions was used to annotate the arrays. The raw fluorescence intensity values were normalised applying quantile normalisation and robust multi-array average (RMA) background correction. ANOVA was performed to identify differentially expressed genes (SAS JMP10 Genomics v6; SAS Institute, Cary, NC, USA). A false-positive rate of  $\alpha = 0.05$  with correction for false discovery rate was taken as the level of significance (GEO: GSE87433). Metabolic memory genes were identified, if they were regulated positively or negatively, in both NC12W → DC12W and NC12W → DC+Tx@12W. Analysis of the resulting gene list was performed using DAVID

bioinformatics database (version 6.7, <https://david-d.ncicrf.gov/>) using the categories UP\_TISSUE and GOTERM\_CC\_FAT.

**Statistical analysis** Metabolic data and pericyte numbers are expressed as mean  $\pm$  SEM and were analysed using one-way ANOVA followed by Tukey's multiple comparison post hoc test. Animals were assigned to experimental groups by simple randomisation. Experimenters were blind to group assignment and outcome assessment. No data, samples or animals were excluded from the reported results.


## Results

The average blood glucose level in healthy control mice (NC) was  $10.4 \pm 1.9$  mmol/l. STZ treatment (DC) resulted in elevation of blood glucose above 33.0 mmol/l. Islet transplantation significantly reduced blood glucose from  $31 \pm 3.7$  mmol/l (DC+Tx@6W) to  $8.4 \pm 1.2$  mmol/l (DC+Tx@12W) (Fig. 1a). Changes in HbA<sub>1c</sub> corresponded to blood glucose levels (data

not shown). Hyperglycaemia was associated with reduced body weight (DC12W  $27.7 \pm 2.3$  g) whereas the transplanted group recovered normal body weight after receiving islet-cell transplantation (DC+Tx@12W  $30.0 \pm 0.8$  g; NC12W  $32.3 \pm 1.4$  g).

To assess microvascular changes, the number of pericytes per retinal capillary area (PC/mm<sup>2</sup>) was determined. Compared with healthy controls ( $1981 \pm 404$  PC/mm<sup>2</sup>), the pericyte coverage of the retinal vasculature was significantly reduced in diabetic mice ( $1571 \pm 383$  PC/mm<sup>2</sup>,  $p < 0.001$ ) and transplanted mice ( $1606 \pm 268$  PC/mm<sup>2</sup>,  $p < 0.001$ ) (Fig. 1b). Endothelial cells were not affected by hyperglycaemic conditions or transplantation (data not shown).

To identify genes involved in hyperglycaemic memory, we analysed expression patterns not regulated by euglycaemic re-entry, with full genome mRNA arrays. One hundred and twenty-six genes were identified as meeting these criteria. The top 25 regulated genes are presented in Fig. 1c; relative expression compared with the NC12W group is shown. Clustering analysis upon functional annotation revealed two compartments affected by hyperglycaemic memory: cytoskeleton and nucleus (Fig. 1d,



**Fig. 1** (a) Average blood glucose levels in healthy controls (NC,  $n = 6$ , dotted line), STZ-diabetic mice (DC,  $n = 6$ , dashed line) and STZ-induced diabetic mice receiving islet transplantation (DC+Tx,  $n = 5$ , solid line). Data are expressed as mean  $\pm$  SEM. (b) Pericyte (PC) coverage of retinal vasculature in healthy controls (NC12W,  $n = 6$ ), STZ-induced diabetic mice (DC12W,  $n = 6$ ) and STZ-induced diabetic mice receiving islet transplantation (DC+Tx@12W,  $n = 4$ ). Data are expressed as mean  $\pm$  SEM. \*\*\* $p < 0.001$  vs NC12W. (c) Heatmap of top 25

upregulated and downregulated memory genes of healthy controls (NC12W,  $n = 5$ ), STZ-induced diabetic mice (DC12W,  $n = 6$ ) and STZ-induced diabetic mice receiving islet transplantation (DC+Tx@12W,  $n = 5$ ). Colour and brightness indicate relative expression change compared with NC12W (green = positive expression change; red = negative expression change). (d) Distribution of regulated memory genes between the cytoskeletal and nuclear compartments

Table 1). The most prominent regulated genes in the cytoskeletal compartment were *Ddx51*, *Fgd4*, *Pdlim7*, *Utp23*, *Cep57*, *Csrp3*, *Eml5*, *Fhl3*, *Map1a*, *Mapk1ip1*, *Mnda*, *Neil2*, *Parp2*, *Myl12b*, *Dynll1*, *Stag3* and *Sntg2*, and in the nuclear compartment were *Ddx51*, *Utp23*, *Mnda*, *Kmt2e*, *Nr6a1*, *Parp2*, *Cdk8*, *Srsf1* and *Zfp326*.

## Discussion

In our study, we demonstrated that changes in gene expression and microvascular damage in the neurovascular unit of the retina in a model of diabetes persisted after euglycaemic re-entry, indicating hyperglycaemic memory.

Euglycaemic re-entry of islet-transplanted mice was confirmed by blood glucose and HbA<sub>1c</sub>. The reduction in HbA<sub>1c</sub> levels mimics the effect seen in diabetic patients on intensive insulin treatment and appears to be greater than the reduction

following sole insulin treatment in animals, which in rodents bears the disadvantage of glucose variability. However, restoration of euglycaemia did not correct microvascular damage, as reflected by sustained reduction in pericyte coverage of the retinal vascular network. This persistence of microvascular damage is considered to be caused by hyperglycaemic memory. Pericytes are an important component of the neurovascular unit, placed at the intersection of the neuroglial and vascular compartments in the retina and are also known to be the first cell type to be damaged under hyperglycaemic conditions [7].

Genes meeting the criteria for hyperglycaemic memory were attributed to the cytoskeletal and nuclear compartments. The cytoskeleton has been shown to be involved in the pathogenesis of diabetic microvascular complications [8, 9]. More importantly, sustained changes in nuclear factors have been reported to have a large-scale impact on gene expression, resulting in changes in antioxidative defence mechanisms to hyperglycaemic stress [10].

**Table 1** Expression changes of cytoskeletal and nuclear proteins

Gene symbol	Gene name	Entrez ID	Fold change vs NC12W	
			DC12W	DC+Tx@12W
<b>Cytoskeleton</b>				
<i>Ddx51</i>	DEAD (Asp-Glu-Ala-Asp) box polypeptide 51	69663	1.14	1.06
<i>Fgd4</i>	FYVE, RhoGEF and PH domain containing 4	224014	1.19	1.17
<i>Pdlim7</i>	PDZ and LIM domain 7	67399	0.87	0.95
<i>Utp23</i>	UTP23, small subunit (SSU) processome component	78581	0.92	0.92
<i>Cep57</i>	Centrosomal protein 57	74360	1.10	1.11
<i>Csrp3</i>	Cysteine and glycine-rich protein 3	13009	0.86	0.88
<i>Eml5</i>	Echinoderm microtubule-associated protein like 5	319670	1.11	1.05
<i>Fhl3</i>	Four and a half LIM domains 3	14201	0.84	0.92
<i>Map1a</i>	Microtubule-associated protein 1 A	17754	0.83	0.89
<i>Mapk1ip1</i>	Mitogen-activated protein kinase 1 interacting protein 1	69546	1.18	1.23
<i>Ifi211</i>	Interferon activated gene 211	381308	0.87	0.95
<i>Neil2</i>	nei like 2 ( <i>E. coli</i> )	382913	1.16	1.21
<i>Parp2</i>	Poly (ADP-ribose) polymerase family, member 2	11546	1.20	1.14
<i>Myl12b</i>	Myosin, light chain 12B, regulatory	67938	0.89	0.90
<i>Dynll1</i>	Dynein light chain LC8-type 1	56455	0.85	0.89
<i>Stag3</i>	Stromal antigen 3	50878	1.22	1.14
<i>Sntg2</i>	Syntrophin, gamma 2	268534	1.17	1.08
<b>Nucleus</b>				
<i>Ddx51</i>	DEAD (Asp-Glu-Ala-Asp) box polypeptide 5	69663	1.14	1.06
<i>Utp23</i>	UTP23, small subunit (SSU) processome component	78581	0.92	0.92
<i>Ifi211</i>	Interferon activated gene 211	381308	0.87	0.95
<i>Kmt2e</i>	Lysine (K)-specific methyltransferase 2E	69188	1.10	1.15
<i>Nr6a1</i>	Nuclear receptor subfamily 6, group A, member 1	14536	1.13	1.06
<i>Parp2</i>	Poly (ADP-ribose) polymerase family, member 2	11546	1.20	1.14
<i>Cdk8</i>	Cyclin-dependent kinase 8	264064	1.16	1.05
<i>Srsf1</i>	Serine/arginine-rich splicing factor 1	110809	1.12	1.06
<i>Zfp326</i>	Zinc finger protein 326	54367	1.10	1.08

Our mouse model of hyperglycaemic memory revealed persistent changes in both gene expression patterns and early structural alterations in the neurovascular unit of the diabetic retina.

**Data availability** The datasets generated during and/or analysed during the current study are available in the GEO repository, GSE87433, <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=idmbysgctluxviv&acc=GSE87433>.

**Funding** This study was supported by the Deutsche Forschungsgemeinschaft (International Research Training group 1874-1 DIAMICOM and the Deutsche Diabetes Gesellschaft).

**Duality of interest** The authors declare that there is no duality of interest associated with this manuscript.

**Contribution statement** PF made substantial contributions to acquisition of data and drafting the article. AS, CS, MK, PW, AD, TL and GM made substantial contributions to analysis and interpretation of data, and revising the article critically for important intellectual content. H-PH made substantial contributions to conception and design, and revising the article critically for important intellectual content. All authors gave final approval of the version to be published. H-PH is responsible for the integrity of the work as a whole.

## References

1. The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group (2015) Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. *Diabetes* 64: 631–642
2. Engerman RL, Kern TS (1987) Progression of incipient diabetic retinopathy during good glycemic control. *Diabetes* 36:808–812
3. Yao D, Taguchi T, Matsumura T et al (2007) High glucose increases angiotensin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. *J Biol Chem* 282:31038–31045
4. El-Osta A, Brasacchio D, Yao D et al (2008) Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. *J Exp Med* 205:2409–2417
5. Tewari S, Zhong Q, Santos JM, Kowluru RA (2012) Mitochondria DNA replication and DNA methylation in the metabolic memory associated with continued progression of diabetic retinopathy. *Invest Ophthalmol Vis Sci* 53:4881–4888
6. Lai Y, Schneider D, Kiszun A et al (2005) Vascular endothelial growth factor increases functional  $\beta$ -cell mass by improvement of angiogenesis of isolated human and murine pancreatic islets. *Transplantation* 79:1530–1536
7. Cogan DG, Toussaint D, Kuwabara T (1961) Retinal vascular patterns. IV. Diabetic retinopathy. *Arch Ophthalmol* 66: 366–378
8. Chang YC, Chang EY, Chuang LM (2015) Recent progress in the genetics of diabetic microvascular complications. *World J Diabetes* 6:715–725
9. Anand A, Bammidi S, Bali P (2014) Cytoskeleton dynamics in the retina. *Crit Rev Eukaryot Gene Expr* 24:255–268
10. Bierhaus A, Schiekofler S, Schwaninger M et al (2001) Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. *Diabetes* 50:2792–2808